Literature DB >> 28767554

COMPARISON OF OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHIC CHANGES AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY ALONE OR IN COMBINATION WITH PHOTODYNAMIC THERAPY IN POLYPOIDAL CHOROIDAL VASCULOPATHY.

Kelvin Yi Chong Teo1,2, Yasuo Yanagi1,2, Shu Yen Lee1,2,3, Ian Yew San Yeo1,2,3,4, Gavin Siew Wei Tan1,2,3, Ranjana Mathur1,2,3, Choi Mun Chan1,2,3, Tien Yin Wong1,2,3,4, Chui Ming Gemmy Cheung1,2,3,4.   

Abstract

PURPOSE: To compare changes in optical coherence tomography angiography in eyes with polypoidal choroidal vasculopathy after treatment with anti-vascular endothelial growth factor monotherapy or combined with photodynamic therapy.
METHODS: This is a longitudinal case-controlled study. The authors performed optical coherence tomography angiography at baseline and Month 3 in patients with treatment-naive polypoidal choroidal vasculopathy undergoing monotherapy (n = 10) or combination therapy (n = 13). We analyzed flow signal within the outer retina and choriocapillaris using automated segmentation. The authors analyzed the presence of pachyvessels using a 10.4-μm segment through Haller layer. The changes in each layer were compared between treatments.
RESULTS: At Month 3, both groups showed similar improvement in best-corrected visual acuity and central retinal thickness. However, flow signal within the polypoidal choroidal vasculopathy complex was decreased in more eyes after combination therapy than after monotherapy (84.6% vs. 40.0%, P = 0.04). Patchy reduction in flow signal within the choriocapillaris layer was noted in 15.4% and 10.0% after combination therapy and monotherapy, respectively (P = 0.61). Significant reduction in pachyvessel caliber was seen only after combination therapy but not after monotherapy (75.0% vs. 0.0%, P = 0.01).
CONCLUSION: Longitudinal optical coherence tomography angiography demonstrates more significant reduction in lesion flow and pachyvessels in the short term after combination therapy than after monotherapy, although visual and structural OCT showed similar improvement.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28767554     DOI: 10.1097/IAE.0000000000001776

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  8 in total

1.  Incidence of Fellow Eye Involvement in Patients With Unilateral Exudative Age-Related Macular Degeneration.

Authors:  Yasuo Yanagi; Aditi Mohla; Shu Yen Lee; Ranjana Mathur; Choi Mun Chan; Ian Yeo; Tien Yin Wong; Chui Ming Gemmy Cheung
Journal:  JAMA Ophthalmol       Date:  2018-08-01       Impact factor: 7.389

2.  Quantitative analysis of branching neovascular networks in polypoidal choroidal vasculopathy by optical coherence tomography angiography after photodynamic therapy and anti-vascular endothelial growth factor combination therapy.

Authors:  Wen-Yi Wang; Chang-Hao Yang; Ta-Ching Chen; Yi-Ting Hsieh; Tzyy-Chang Ho; Chung-May Yang; Fang-Yu Liu; Tso-Ting Lai
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-02-08       Impact factor: 3.117

3.  Choroidal morphology and short-term outcomes of combination photodynamic therapy in polypoidal choroidal vasculopathy.

Authors:  Jiwon Baek; Jae Hyung Lee; Sohee Jeon; Won Ki Lee
Journal:  Eye (Lond)       Date:  2018-10-10       Impact factor: 3.775

4.  Association between pachychoroid and long-term treatment outcomes of photodynamic therapy with intravitreal ranibizumab for polypoidal choroidal vasculopathy.

Authors:  Keiko Azuma; Atsushi Okubo; Yoko Nomura; Hanpeng Zhou; Ryo Terao; Yohei Hashimoto; Kimiko Shimizu Asano; Kunihiro Azuma; Tatsuya Inoue; Ryo Obata
Journal:  Sci Rep       Date:  2020-05-20       Impact factor: 4.379

5.  One-Year Efficacy and Safety of Proton-Beam Irradiation Combined with Intravitreal Conbercept for Refractory or Recurrent Polypoidal Choroidal Vasculopathy: A Pilot Study.

Authors:  Jingli Guo; Xianxin Qiu; Wenyi Tang; Gezhi Xu; Michael F Moyers; Wei Ren; Ying Xing; Jin Gao; Jiayao Sun; Jiade Lu; Lin Kong; Wei Liu
Journal:  Ophthalmol Ther       Date:  2021-11-13

6.  Novel volumetric imaging biomarkers for assessing disease activity in eyes with PCV.

Authors:  Chinmayi Himanshuroy Vyas; Chui Ming Gemmy Cheung; Janice Marie N Jordan-Yu; Hitoshi Shimizu; Anna Cheng Sim Tan; Shaun Sebastian Sim; Beau James Fenner; Masahiro Akiba; Usha Chakravarthy; Kelvin Yi Chong Teo
Journal:  Sci Rep       Date:  2022-02-22       Impact factor: 4.379

7.  Multicentre, randomised clinical trial comparing intravitreal aflibercept monotherapy versus aflibercept combined with reduced-fluence photodynamic therapy (RF-PDT) for the treatment of polypoidal choroidal vasculopathy.

Authors:  Chinmayi Himanshuroy Vyas; Chui Ming Gemmy Cheung; Colin Tan; Caroline Chee; Kelly Wong; Janice Marie N Jordan-Yu; Tien Yin Wong; Anna Tan; Beau Fenner; Shaun Sim; Kelvin Yi Chong Teo
Journal:  BMJ Open       Date:  2021-07-15       Impact factor: 2.692

Review 8.  Evolving treatment paradigms for PCV.

Authors:  Beau J Fenner; Chui Ming Gemmy Cheung; Shaun S Sim; Won Ki Lee; Giovanni Staurenghi; Timothy Y Y Lai; Paisan Ruamviboonsuk; Gregg Kokame; Yasuo Yanagi; Kelvin Y C Teo
Journal:  Eye (Lond)       Date:  2021-07-14       Impact factor: 3.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.